Sector News

Reuters: Rare disease drugmaker PTC Therapeutics explores sale – sources

February 25, 2015
Life sciences
(Reuters) – Rare disease drugmaker PTC Therapeutics Inc (PTCT.O) is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc (SHP.L) and BioMarin Pharmaceutical Inc (BMRN.O), according to people familiar with the matter.
 
The company, which treats a muscle-wasting disorder known as Duchenne, is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private.
 
Representatives for South Plainfield, New Jersey-based PTC Therapeutics could not be reached for comment. Representatives for Shire and BioMarin declined to comment.
 
The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to $68.44 on reports of the potential sale, before easing to $63.51, up 15.1 percent.
 
Makers of treatments for rare diseases, also known as orphans, are attractive acquisitions for large pharmaceutical companies looking to offset a drop in sales as patents on their blockbuster products expire.
 
Prosena Holding NV, which also makes a treatment for Duchenne, was acquired last November by BioMarin for $840 million.
 
PTC Therapeutics’ drug Translarna has received orphan drug status in the European Union and the United States and is in process of seeking U.S. Food and Drug Administration approval.
 
Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.
 
Shire has made several acquisitions to bolster its focus on rare diseases, including a $5.2 billion purchase of NPS Pharmaceuticals in January and a $4.2 billion deal for ViroPharma last year.
 
It also took a look at acquiring Salix Pharmaceuticals Ltd (SLXP.O) in recent weeks but ended up passing on the deal, according to sources.
 
(Reporting by Olivia Oran and Soyoung Kim in New York; Editing by Christian Plumb and Jeffrey Benkoe)

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.